Get the Stockscreener App
2.33
4.12%
-0.10
Polaryx Therapeutics Inc stock is traded at $2.33, with a volume of 129.74K.
It is down -4.12% in the last 24 hours and up +3.10% over the past month.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
See More
Previous Close:
$2.43
Open:
$2.4
24h Volume:
129.74K
Relative Volume:
0.61
Market Cap:
$116.14M
Revenue:
-
Net Income/Loss:
$-6.48M
P/E Ratio:
-17.01
EPS:
-0.137
Net Cash Flow:
$-5.30M
1W Performance:
-17.08%
1M Performance:
+3.10%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$2.25
$2.44
1-Week Range:
$2.25
$2.88
52-Week Range:
$2.01
$33.90
Polaryx Therapeutics Inc Stock (PLYX) Company Profile
Name
Polaryx Therapeutics Inc
Sector
Industry
Phone
201-940-7236
Address
140 EAST RIDGEWOOD AVENUE, PARAMUS
Compare PLYX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLYX
Polaryx Therapeutics Inc
|
2.33 | 116.14M | 0 | -6.48M | -5.30M | -0.137 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Initiated | Maxim Group | Buy |
Polaryx Therapeutics Inc Stock (PLYX) Latest News
PLYX News Today | Why did Polaryx Therapeutics stock drop today? - MarketBeat
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
H.C. Wainwright initiates Polaryx Therapeutics stock with buy rating - Investing.com
PLYX Initiates Coverage On Polaryx Therapeutics -- Price Target Set at $7.00 - GuruFocus
Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co. - Moomoo
Operating cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Free cash flow per share of Polaryx Therapeutics, Inc. – FWB:1V8 - TradingView
Polaryx Therapeutics (PLYX) Holds Steady Near Support as Technical Indicators Signal ConsolidationDeath Cross - dars.gov.et
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
Enterprise value to EBIT forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Enterprise value to revenue forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to sales forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Price to earnings forward of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView
Polaryx Therapeutics, Inc. Actuals & Estimates (NASDAQ:PLYX) - TradingView
PLYX Forecast — Price Target — Prediction for 2027 - TradingView
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Ord Shs (PLYX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polaryx Therapeutics Ord Shs - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polaryx Therapeutics Ord Shs (PLYX) Institutional Confidence - TradingKey
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Polaryx Therapeutics (PLYX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Faces Pressure After 6.7% Drop: Key Support Levels in FocusHead and Shoulders - newsline.com
Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Polaryx Therapeutics (PLYX) Stock Chart and Price History 2026 - MarketBeat
Polaryx Therapeutics CEO’s Mstone buys $360,003 in PLYX stock By Investing.com - Investing.com Australia
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
Polaryx Therapeutics CEO’s Mstone buys $360,003 in PLYX stock - Investing.com
MStone affiliate of Polaryx Therapeutics (PLYX) buys 88K common shares - Stock Titan
PLYXPolaryx Therapeutics Inc. stock news, filings & ratings - Quantisnow
Polaryx (PLYX) secures $10M PIPE to fund SOTERIA trial and extend runway to Q2 2027 - Stock Titan
Why Polaryx Therapeutics Stock Is Surging On Thursday? - Benzinga
Polaryx Therapeutics closes $10 million PIPE financing By Investing.com - Investing.com Nigeria
Polaryx Therapeutics closes $10 million PIPE financing - Investing.com
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial - marketscreener.com
Polaryx Therapeutics (PLYX) Surges Nearly 20%: Key Levels to Watch After the BreakoutCovered Call Trade - dars.gov.et
Polaryx Therapeutics, Inc. announced that it has received $10.010784 million in funding - marketscreener.com
Polaryx Therapeutics (PLYX) Slips 2.71% as Stock Tests Key Support Near $2.38Growth ETF - The Legal Advocate
Polaryx Therapeutics (PLYX) Retreats Toward Support Amid Selling PressureETF Outflow Streak - Město Břeclav
thanks & goodnight ! - Moomoo
Polaryx Therapeutics (PLYX) Slips 8.63% as Biotech Volatility Resurfaces – Key Support Levels in FocusFactor Valuation - dars.gov.et
PLYX Technical Analysis | Trend, Signals & Chart Patterns | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) narrows loss but flags going concern risk - Stock Titan
Polaryx Therapeutics 1Q 2026: Net income $(2.54M), EPS $(0.05) — 10-Q Summary - TradingView
Polaryx Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Polaryx Therapeutics Awarded Double Honors at the 2026 GHP Healthcare & Pharmaceutical Awards - Quiver Quantitative
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards - The Manila Times
Polaryx Therapeutics Inc Stock (PLYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):